A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become
available, extending progression-free and overall survival for patients in meaningful ways …

First-line chemotherapy for many solid tumors is limited by toxicity. There is a growing
interest in maintenance therapy as a strategy for prolonging the benefits of first-line therapy …

In advanced-stage cutaneous T-cell lymphoma (CTCL), the current therapeutic options
rarely provide long-lasting responses, leaving allogenic stem-cell transplantation the only …

Drug development is paramount to improve outcomes in patients with gynecologic cancers.
A randomized clinical trial should measure whether a clinically relevant improvement is …

The management of patients with advanced non-small-cell lung cancer (NSCLC) is
becoming increasingly complex, with the identification of driver mutations/rearrangements …

Abstract Purpose of Review While the traditional gold standard for demonstrating clinical
benefit of a therapy has been to show prolongation of overall survival (OS), there are …

Epithelial ovarian cancer has a very high rate of relapse after primary therapy; historically
approximately 70% of patients with a complete clinical response to surgery and adjuvant …

Over the past few decades, platinum-based combination chemotherapy (PBCC) has been
the preferred initial therapy for metastatic urothelial cancer (mUC). However, despite a …

The interest in maintenance therapy for patients with advanced cancers has been rapidly
growing. Maintenance therapy is a useful strategy that may strengthen results of induction …

A recent report from the ATLAS trial comparing different maintenance strategies following
haematopoeitic stem cell transplantation for multiple myeloma provides an opportunity to …